SAREPTA THERAPEUTICS, INC. Payments to Acquire Debt Securities, Available-for-sale
SAREPTA THERAPEUTICS, INC. (SRPT) reported Payments to Acquire Debt Securities, Available-for-sale of $170.20 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-05-06
- SAREPTA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $170.20M, a 281.11% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $44.66M, a 95.94% decline from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $1.10B, a 46.23% decline from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $2.04B, a 5.58% increase from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $1.94B, a 6358.77% increase from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-03-31 | $170.20M 10-Q · filed 2026-05-06 | $170.20M derived: sum of 2 quarters · filed 2026-05-06 | $170.20M derived: sum of 3 quarters · filed 2026-05-06 | $170.20M derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $44.66M 10-K · filed 2026-03-02 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $44.66M 10-Q · filed 2025-11-06 | $207.57M derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $44.66M 10-Q · filed 2025-08-06 | $207.57M derived: sum of 3 quarters · filed 2026-05-06 | $596.97M derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-03-31 | $44.66M 10-Q · filed 2026-05-06 | $207.57M derived: sum of 2 quarters · filed 2026-05-06 | $596.97M derived: sum of 3 quarters · filed 2026-05-06 | $927.80M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $162.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $552.31M derived: sum of 2 quarters · filed 2026-03-02 | $883.14M derived: sum of 3 quarters · filed 2026-03-02 | $1.10B 10-K · filed 2026-03-02 |
| 2024-09-30 | $389.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $720.23M derived: sum of 2 quarters · filed 2025-11-06 | $936.68M 10-Q · filed 2025-11-06 | $1.51B derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $330.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $547.28M 10-Q · filed 2025-08-06 | $1.12B derived: sum of 3 quarters · filed 2026-03-02 | $1.76B derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $216.45M 10-Q · filed 2025-05-06 | $785.99M derived: sum of 2 quarters · filed 2026-03-02 | $1.43B derived: sum of 3 quarters · filed 2026-03-02 | $1.83B derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $569.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.22B derived: sum of 2 quarters · filed 2026-03-02 | $1.62B derived: sum of 3 quarters · filed 2026-03-02 | $2.04B 10-K · filed 2026-03-02 |
| 2023-09-30 | $645.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.05B derived: sum of 2 quarters · filed 2024-11-06 | $1.48B 10-Q · filed 2024-11-06 | $1.90B derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $403.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $829.80M 10-Q · filed 2024-08-07 | $1.26B derived: sum of 3 quarters · filed 2025-02-28 | $1.63B derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $426.76M 10-Q · filed 2024-05-01 | $854.30M derived: sum of 2 quarters · filed 2025-02-28 | $1.23B derived: sum of 3 quarters · filed 2025-02-28 | $1.58B derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $427.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $799.25M derived: sum of 2 quarters · filed 2025-02-28 | $1.16B derived: sum of 3 quarters · filed 2025-02-28 | $1.94B 10-K · filed 2025-02-28 |
| 2022-09-30 | $371.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $729.55M derived: sum of 2 quarters · filed 2023-11-01 | $1.51B 10-Q · filed 2023-11-01 | $1.51B derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $357.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $1.14B 10-Q · filed 2023-08-02 | $1.14B derived: sum of 3 quarters · filed 2024-02-28 | $1.14B derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $779.77M 10-Q · filed 2023-05-02 | $779.77M derived: sum of 2 quarters · filed 2024-02-28 | $779.77M derived: sum of 3 quarters · filed 2024-02-28 | $779.77M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$1.00K derived: sum of 2 quarters · filed 2024-02-28 | -$1.00K derived: sum of 3 quarters · filed 2024-02-28 | $29.99M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$1.00K derived: sum of 2 quarters · filed 2022-11-02 | $29.99M 10-Q · filed 2022-11-02 | $465.87M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $29.99M 10-Q · filed 2022-08-02 | $465.87M derived: sum of 3 quarters · filed 2023-02-28 | $606.82M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $29.99M 10-Q · filed 2022-05-04 | $465.87M derived: sum of 2 quarters · filed 2023-02-28 | $606.82M derived: sum of 3 quarters · filed 2023-02-28 | $998.12M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $435.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $576.83M derived: sum of 2 quarters · filed 2023-02-28 | $968.13M derived: sum of 3 quarters · filed 2023-02-28 | $1.33B 10-K · filed 2023-02-28 |
| 2020-09-30 | $140.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $532.25M derived: sum of 2 quarters · filed 2021-11-03 | $897.69M 10-Q · filed 2021-11-03 | $1.11B derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $391.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $756.74M 10-Q · filed 2021-08-04 | $966.14M derived: sum of 3 quarters · filed 2022-03-01 | $1.22B derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $365.44M 10-Q · filed 2021-05-05 | $574.84M derived: sum of 2 quarters · filed 2022-03-01 | $827.78M derived: sum of 3 quarters · filed 2022-03-01 | $1.06B derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $209.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $462.34M derived: sum of 2 quarters · filed 2022-03-01 | $699.15M derived: sum of 3 quarters · filed 2022-03-01 | $1.19B 10-K · filed 2022-03-01 |
| 2019-09-30 | $252.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $489.74M derived: sum of 2 quarters · filed 2020-11-05 | $984.23M 10-Q · filed 2020-11-05 | $1.50B derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $236.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $731.29M 10-Q · filed 2020-08-05 | $1.25B derived: sum of 3 quarters · filed 2021-03-01 | $1.61B derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $494.48M 10-Q · filed 2020-05-06 | $1.01B derived: sum of 2 quarters · filed 2021-03-01 | $1.37B derived: sum of 3 quarters · filed 2021-03-01 | $1.57B derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $520.22M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $875.78M derived: sum of 2 quarters · filed 2021-03-01 | $1.08B derived: sum of 3 quarters · filed 2021-03-01 | $1.17B 10-K · filed 2021-03-01 |
| 2018-09-30 | $355.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $559.87M derived: sum of 2 quarters · filed 2019-11-07 | $651.39M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $204.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $295.82M 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $91.51M 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | $589.52M 10-K · filed 2020-02-26 | |||
| 2016-12-31 | $195.43M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |